OptimizeRx to Part Ways With Chief Commercial Officer Theresa Greco Effective June 15
OptimizeRx said Chief Commercial Officer Theresa Greco will leave the role effective June 15, 2026, under a separation agreement, and will then serve as an advisor through June 15, 2027. The filing says the agreement provides 12 months of base salary at $380,000 per year, a $209,000 lump-sum bonus, and COBRA premium reimbursement, which shareholders may track as a cost of the executive transition.
Key points
- Theresa Greco's separation is effective June 15, 2026; the separation agreement was signed June 1, 2026 and becomes enforceable June 9, 2026, absent revocation.
- Greco will receive 12 months of base salary at $380,000 per year, a $209,000 lump-sum payment of her annual cash bonus target, and COBRA premium reimbursement for 12 months.
- Greco will serve as an advisor for 12 months through June 15, 2027, with equity previously granted continuing to vest; she is also subject to 12-month non-compete and non-solicitation terms.
- The full agreement will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.